Finance1 min read

Biotech funding froze. Why has this lab instrument maker climbed 25% anyway?

By · Via Investing.com Markets · Published by Everything Blog

In short

A lab instrument maker has seen its stock climb 25% despite a broader freeze in biotechnology funding. Further details explaining the specific drivers behind the company's market gain were not disclosed in the initial report.

Key points

  • A lab instrument maker has seen its stock climb 25% despite a broader freeze in biotechno…: A lab instrument maker has seen its stock climb 25% despite a broader freeze in biotechnology funding.
  • Further details explaining the specific drivers behind the company's market gain were not…: Further details explaining the specific drivers behind the company's market gain were not disclosed in the initial report.
Finance